Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,144 public trials 2,036 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
Locations
  • Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Cancer Center Duarte, California, United States
  • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
View all 120 locations
View Trial Details
Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Goodyear, Arizona, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site Anaheim, California, United States
  • Research Site Los Angeles, California, United States
View all 155 locations
View Trial Details
Active, not recruiting

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +21 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
View all 84 locations
View Trial Details
Active, not recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

NCT04626791

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Mount Sinai Hospital New York, United States
  • Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina, United States
  • University of Washington Medical Center - Montlake Seattle, Washington, United States
View Trial Details
Active, not recruiting

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

NCT03016871

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • Fred Hutchinson Cancer Research Center Seattle, Washington, United States
View Trial Details
Active, not recruiting

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia Alessandria, Italy
  • A.O.U. Ospedali Riuniti - Clinica di Ematologia Ancona, Italy
  • Ospedale C. e G. Mazzoni - U.O.C. di Ematologia Ascoli Piceno, Italy
  • AOU Policlinico Consorziale - U.O. Ematologia con Trapianto Bari, Italy
View all 23 locations
View Trial Details
Active, not recruiting

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

NCT06970743

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Peking University Peoples Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 56 locations
View Trial Details

Related conditions